Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids
RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants David Connolly - IR & Corporate Communications David Meeker - Chairman, CEO & President Jennifer Lee - EVP & Head, North America Hunter Smith - CFO Yann Mazabraud - EVP & Head, International Conference Call Participants Jeff Hung - Morgan Stanley Phil Nadeau - TD Cowen Whitney Ijem - Canaccord Genuity Dae Gon Ha - Stifel Corinne Johnson - Goldman Sachs Tazeen Ahmad - BofA Securities Joseph Stringer - Needham & Company Michael Higgins - Ladenburg Thalmann Operator Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Second Quarter 2024 Earnings Conference Call.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.82 per share a year ago.
